Uruguay: These 7 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025

DrugPatentWatch^® Estimated Loss of Exclusivity Dates in Uruguay

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

Summary: Uruguay: These 7 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025

Subscribe to access the full database, or Sign Up
Tradename	Ingredient	Estimated Entry Opportunity Date
OLYSIO	simeprevir sodium	2025-07-29
NEVANAC	nepafenac	2024-12-02
LYRICA CR	pregabalin	2025-11-02
CORLANOR	ivabradine hydrochloride	2025-02-28
CORLANOR	ivabradine	2025-02-28
WAKIX	pitolisant hydrochloride	2025-02-10
>Tradename	>Ingredient	>Estimated Entry Opportunity Date

Details: Uruguay: These 7 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025

When can OLYSIO (simeprevir sodium) generic drug versions launch?

Generic name: simeprevir sodium
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 29, 2025
Generic Entry Controlled by: Uruguay Patent 29,703

OLYSIO is a drug marketed by Janssen Prods. There are nine patents protecting this drug.

This drug has one hundred and thirty-nine patent family members in forty-three countries.

See drug price trends for OLYSIO.

The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.

When can NEVANAC (nepafenac) generic drug versions launch?

Generic name: nepafenac
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 02, 2024
Generic Entry Controlled by: Uruguay Patent 29,238

NEVANAC is a drug marketed by Harrow Eye. There are three patents protecting this drug.

This drug has twenty-seven patent family members in twenty-three countries.

See drug price trends for NEVANAC.

The generic ingredient in NEVANAC is nepafenac. There are eight drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the nepafenac profile page.

When can LYRICA CR (pregabalin) generic drug versions launch?

Generic name: pregabalin
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 02, 2025
Generic Entry Controlled by: Uruguay Patent 29,890

LYRICA CR is a drug marketed by Upjohn. There are three patents protecting this drug and four Paragraph IV challenges. Eight tentatively approved generics are ready to enter the market.

This drug has thirty-seven patent family members in thirty-three countries.

See drug price trends for LYRICA CR.

The generic ingredient in LYRICA CR is pregabalin. There are forty-one drug master file entries for this API. Fifty-six suppliers are listed for this generic product. Additional details are available on the pregabalin profile page.

When can CORLANOR (ivabradine hydrochloride) generic drug versions launch?

Generic name: ivabradine hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 28, 2025
Generic Entry Controlled by: Uruguay Patent 29,405

CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.

When can CORLANOR (ivabradine) generic drug versions launch?

Generic name: ivabradine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 28, 2025
Generic Entry Controlled by: Uruguay Patent 29,406

CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine profile page.

When can WAKIX (pitolisant hydrochloride) generic drug versions launch?

Generic name: pitolisant hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 10, 2025
Generic Entry Controlled by: Uruguay Patent 29,369

WAKIX is a drug marketed by Harmony. There are three patents protecting this drug.

This drug has sixty-one patent family members in thirty-one countries. There has been litigation on patents covering WAKIX

See drug price trends for WAKIX.

The generic ingredient in WAKIX is pitolisant hydrochloride. One supplier is listed for this generic product. Additional details are available on the pitolisant hydrochloride profile page.

When can NEXAVAR (sorafenib tosylate) generic drug versions launch?

Generic name: sorafenib tosylate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 07, 2025
Generic Entry Controlled by: Uruguay Patent 29,410

NEXAVAR is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-nine patent family members in thirty-nine countries. There has been litigation on patents covering NEXAVAR

See drug price trends for NEXAVAR.

The generic ingredient in NEXAVAR is sorafenib tosylate. There are thirteen drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the sorafenib tosylate profile page.